Direct ISR target engagement likely requires trazodone doses around 150-200 mg/day for disease-modifying effects in dementia

Target: EIF2AK3; EIF2S1; ATF4; DDIT3 Composite Score: 0.590 Price: $0.50 Citation Quality: Pending neurodegeneration Status: proposed ⬇+1 (1 reviews)
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
⚠ Missing Evidence⚠ Low Validation⚠ Orphaned Senate Quality Gates →
Quality Report Card click to collapse
C+
Composite: 0.590
Top 53% of 1402 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.79 Top 26%
B Evidence Strength 15% 0.68 Top 31%
B Novelty 12% 0.62 Top 71%
C+ Feasibility 12% 0.52 Top 60%
B+ Impact 12% 0.71 Top 41%
C+ Druggability 10% 0.55 Top 53%
D Safety Profile 8% 0.36 Top 88%
C+ Competition 6% 0.58 Top 69%
C+ Data Availability 5% 0.57 Top 60%
C+ Reproducibility 5% 0.54 Top 64%
Evidence
4 supporting | 3 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

Description

The most credible disease-modifying model is that trazodone must reach a higher exposure range, likely around 150-200 mg/day, to engage the PERK-eIF2alpha integrated stress response in neurons and restore translation. This remains a mechanistically grounded but unvalidated human threshold derived mainly from preclinical tauopathy/prion data and supported by the observation that many real-world dementia prescriptions were likely below this range.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Target Gene: EIF2AK3 EIF2S1 ATF4 DDIT3"]
    B["Molecular Mechanism
Pathway Activation"] C["Cellular Phenotype
Neuronal / Glial Response"] D["Network Effect
Circuit-Level Consequence"] E["Disease Relevance
Neurodegeneration Link"] A --> B --> C --> D --> E style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style E fill:#1b5e20,stroke:#81c784,color:#81c784

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.79 (15%) Evidence 0.68 (15%) Novelty 0.62 (12%) Feasibility 0.52 (12%) Impact 0.71 (12%) Druggability 0.55 (10%) Safety 0.36 (8%) Competition 0.58 (6%) Data Avail. 0.57 (5%) Reproducible 0.54 (5%) KG Connect 0.50 (8%) 0.590 composite
7 citations 7 with PMID Validation: 0% 4 supporting / 3 opposing
For (4)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
3
1
MECH 3CLIN 3GENE 0EPID 1
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Trazodone rescued neurodegeneration and reversed e…SupportingCLIN----PMID:28430857-
Follow-up proteomics showed trazodone rescued syna…SupportingEPID----PMID:37703312-
AD brains show activated UPR/ISR biology, supporti…SupportingMECH----PMID:15973543-
Phosphorylated eIF2alpha colocalizes with degenera…SupportingMECH----PMID:12499843-
The proposed ~194 mg/day threshold is a mouse-to-h…OpposingMECH----PMID:28430857-
Human clinical pharmacology at common doses is dom…OpposingCLIN----PMID:29332554-
Naturalistic dementia cohort data do not establish…OpposingCLIN----PMID:35921312-
Legacy Card View — expandable citation cards

Supporting Evidence 4

Trazodone rescued neurodegeneration and reversed eIF2alpha-P-linked translational repression in mouse prion an…
Trazodone rescued neurodegeneration and reversed eIF2alpha-P-linked translational repression in mouse prion and tauopathy models, with authors mapping efficacious exposure to a clinically relevant human dose estimate.
Follow-up proteomics showed trazodone rescued synaptic and mitochondrial nascent proteomes downstream of ISR d…
Follow-up proteomics showed trazodone rescued synaptic and mitochondrial nascent proteomes downstream of ISR dysregulation.
AD brains show activated UPR/ISR biology, supporting target relevance in human disease.
Phosphorylated eIF2alpha colocalizes with degenerating tau-positive neurons in AD.

Opposing Evidence 3

The proposed ~194 mg/day threshold is a mouse-to-human extrapolation, not a demonstrated human CNS target-enga…
The proposed ~194 mg/day threshold is a mouse-to-human extrapolation, not a demonstrated human CNS target-engagement threshold.
Human clinical pharmacology at common doses is dominated by receptor occupancy and sedative effects, making me…
Human clinical pharmacology at common doses is dominated by receptor occupancy and sedative effects, making mechanistic attribution uncertain.
Naturalistic dementia cohort data do not establish disease modification at any dose and were heavily confounde…
Naturalistic dementia cohort data do not establish disease modification at any dose and were heavily confounded by low exposure and indication bias.
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

0.580.590.60 0.61 0.57 2026-04-252026-04-252026-04-25 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (6)

Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease.
Neuroreport (2003) · PMID:12499843
No extracted figures yet
The unfolded protein response is activated in Alzheimer's disease.
Acta neuropathologica (2005) · PMID:15973543
No extracted figures yet
Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice.
Brain : a journal of neurology (2017) · PMID:28430857
No extracted figures yet
Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets.
Journal of psychopharmacology (Oxford, England) (2019) · PMID:29332554
No extracted figures yet
Trazodone and patient outcomes in dementia-Limitations of naturalistic cohort data.
International journal of geriatric psychiatry (2022) · PMID:35921312
No extracted figures yet
Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration.
Brain : a journal of neurology (2024) · PMID:37703312
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
31.7th percentile (747 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.640

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target
Score: 7.200 | neurodegeneration
Enteric Nervous System Dysfunction as Self-Reinforcing Pathological Loop
Score: 7.000 | neurodegeneration
Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation
Score: 6.000 | neurodegeneration
SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration
Score: 5.500 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 EIF2AK3; — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for EIF2AK3; structures...
Querying Protein Data Bank API

Community Feedback

1 1 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)